- NBA bans Bucks guard Beverley four games for tossing balls at fans
- Wimbledon chiefs say more of planned expansion will be public parkland
- Argentina's Milei faces 2nd general strike in 5 months
- Low-cost MRI paired with AI produces high-quality results
- Judge tosses California children's pollution suit against US govt
- Pope's holy year causes transport jitters for Rome
- American 14-year-old talent signs MLS pro deal with Man City awaiting
- Nadal wants to lose fear factor after winning Rome opener
- UN official says Israel closure of Gaza crossings 'completely crippling' aid
- Panama Papers law firm boss Ramon Fonseca dead
- Eurovision draws street protests calling for Israel's ejection
- Stormy Daniels denies cashing in on claimed tryst with Trump
- Spain govt vows to block hostile BBVA bid for rival bank
- In south Brazil, race on to deliver aid ahead of new storms
- NHL Maple Leafs fire Keefe as coach after first-round exit
- Porsche recalls thousands of Taycans over faulty batteries
- Sanchez escapes through dust and gravel for nervy Giro triumph
- RFU warn England rugby star Billy Vunipola after Mallorca arrest
- Forest have 'moved on' from failed points deduction appeal, says Nuno
- Dyche unable to 'crack on' with Everton rebuild during takeover saga
- Stormy Daniels denies cashing in on claims of tryst with Trump
- Trump's son Barron, 18, named Republican delegate
- Mbappe gets ready to say goodbye as PSG digest Champions League exit
- Nadal squeezes past qualifier Bergs in Rome opener
- Boeing passenger plane exits runway in Senegal injuring 11
- Chessum in doubt for England's tour of Japan and New Zealand
- UK's Cameron calls for Israel to produce 'clear plan' for Rafah
- Cate Blanchett to be honoured at San Sebastian film festival
- Olympic torch relay in Marseille offers 'solidarity' with Ukraine
- Jorginho targets silverware after signing new Arsenal deal
- Stormy Daniels back in the Trump trial hot seat
- Scientists win World Food Prize for work on Global Seed Vault
- London, Frankfurt stocks hit record highs on rate-cut hopes
- Israel hits Rafah despite US warning on arms transfers
- Atletico win appeal over racist abuse sanction
- Nepal's nature threatened by new development push: conservationists
- Russell returns from injury to bolster Bath's bid for Premiership title
- Cate Blanchett to be honoured by San Sebastian film festival
- Charity warns Italy's ban on NGO planes risks lives
- Celtic captain McGregor urges Hoops to 'stay calm' against Rangers
- Olympic javelin champion Chopra targets 90m mark in Doha
- Norris backs McLaren to mount 2025 F1 title bid after Miami win
- London, Frankfurt hit record highs on rate-cut hopes
- UK's Cameron urges NATO countries to boost defence spending
- Bank of England holds rate at 16-year high, signals looming cut
- Spanish court shelves Shakira tax fraud case
- Bayern face uncertain future after Champions League exit
- Rafah struck after Biden warning on arms transfers
- European stocks stutter before Bank of England rate call
- Italian tennis star Giorgi retires
US approves gene therapy treatment for hemophilia
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.
Beqvez, which is given as a single intravenous infusion, was shown in a clinical trial of 45 people to be better at preventing bleeding among adults with moderate to severe hemophilia B, compared to regular infusions of a protein that promotes clotting, called protein factor IX (FIX).
The current standard of care is cumbersome, requiring infusions up to several times per week.
"Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues," said Adam Cuker, director of the University of Pennsylvania's Comprehensive Hemophilia and Thrombosis Program, in a Pfizer statement.
"A one-time treatment with BEQVEZ has the potential to be transformative for appropriate patients by reducing both the medical and treatment burden over the long term."
The therapy was generally well tolerated but a common side effect was elevated liver enzymes, a sign of liver inflammation that wasn't accompanied by outward symptoms. Still, patients are advised to avoid alcohol for up to a year following their treatment, to prevent liver damage.
Patients will be followed up to gather more data for up to 15 years.
Pfizer's genetic therapy targets hemophilia B, the second most common form of the condition, which primarily affects males. More than 38,000 people worldwide live with hemophilia B, according to the World Federation of Hemophilia.
It works by infecting the body with a virus, modified to be harmless, which delivers a functional copy of the factor IX gene to liver cells, instructing them to produce the protein that promotes clotting that the patient otherwise lacks.
It received approval by Canada in January and is awaiting review by the European Medicines Agency.
Pfizer's statement did not mention a list price, which is often a limiting factor for gene therapy treatments. Recently approved sickle cell gene therapies run to $3 to $4 million before insurance.
B.Shevchenko--BTB